Literature DB >> 16526056

Mutational analysis of the cell cycle inhibitor Kip1/p27 in childhood leukemia.

E-A Markaki1, E Stiakaki, A Zafiropoulos, D A Arvanitis, N Katzilakis, H Dimitriou, D A Spandidos, M Kalmanti.   

Abstract

BACKGROUND: Cyclin-dependent kinases (CDKs) and cyclins, their regulatory subunits, govern cell-cycle progression in eukaryotic cells. Kip1/p27 is the main cyclin-dependent kinase inhibitor, which arrests cell division inhibiting G1-S transition. Kip1/p27 seems to play a critical role in the pathogenesis of several human malignancies and its lower expression has been shown to correlate with a poor prognosis in adult solid tumors.
METHODS: Bone marrow blasts from 49 children with leukemia, 37 acute lymphoblastic leukemia (ALL), and 12 acute myeloid leukemia (AML) were studied. Exon 3 of Kip1/p27 was amplified using the polymerase chain reaction technique (PCR). Single strand conformational polymorphism and heterodouplex analysis were performed to detect DNA sequence with altered conformations and were subsequently sequenced to document mutations.
RESULTS: Mutations in Kip1/p27 gene were detected in 2 out of 3 T-ALL, 6 out of 12 AML patients, and only 1 out of 34 B lineage ALL cases. Although the patient groups are small, a highly significant relation of the mutation status with the type of leukemia (P = 0.0037) and the risk group according to treatment protocols (P = 0.00021) was estimated. A statistically significant difference in the white blood count was observed (P = 0.019) between the mutated and non-mutated patient groups although no statistically significant association of the mutation status with the hemoglobin and platelets values, karyotype, age, sex, disease progression, and outcome was determined.
CONCLUSIONS: Based upon these results, the Kip1/p27 mutations should be considered for further prospective testing as an additional parameter for risk stratification and treatment of childhood leukemia. Copyright 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16526056     DOI: 10.1002/pbc.20730

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  7 in total

1.  Somatic mutation and germline sequence abnormalities in CDKN1B, encoding p27Kip1, in sporadic parathyroid adenomas.

Authors:  Jessica Costa-Guda; Ilaria Marinoni; Sara Molatore; Natalia S Pellegata; Andrew Arnold
Journal:  J Clin Endocrinol Metab       Date:  2011-02-02       Impact factor: 5.958

2.  Proteolytically cleaved MLL subunits are susceptible to distinct degradation pathways.

Authors:  Akihiko Yokoyama; Francesca Ficara; Mark J Murphy; Christian Meisel; Alpana Naresh; Issay Kitabayashi; Michael L Cleary
Journal:  J Cell Sci       Date:  2011-07-01       Impact factor: 5.285

3.  p27 inhibits CDK6/CCND1 complex formation resulting in cell cycle arrest and inhibition of cell proliferation.

Authors:  Niannian Li; Jie Zeng; Fuze Sun; Xiaoling Tong; Gang Meng; Chunman Wu; Xin Ding; Lanlan Liu; Minjin Han; Cheng Lu; Fangyin Dai
Journal:  Cell Cycle       Date:  2018-10-24       Impact factor: 4.534

Review 4.  Prognostification of ALL by Cytogenetics.

Authors:  Ansar Hakeem; Aejaz Aziz Shiekh; Gull Mohd Bhat; A R Lone
Journal:  Indian J Hematol Blood Transfus       Date:  2014-12-11       Impact factor: 0.900

Review 5.  Cytogenetic and molecular predictors of outcome in acute lymphocytic leukemia: recent developments.

Authors:  Ilaria Iacobucci; Cristina Papayannidis; Annalisa Lonetti; Anna Ferrari; Michele Baccarani; Giovanni Martinelli
Journal:  Curr Hematol Malig Rep       Date:  2012-06       Impact factor: 3.952

6.  Drug targets for cell cycle dysregulators in leukemogenesis: in silico docking studies.

Authors:  Archana Jayaraman; Kaiser Jamil
Journal:  PLoS One       Date:  2014-01-15       Impact factor: 3.240

7.  Haploinsufficiency of ETV6 and CDKN1B in patients with acute myeloid leukemia and complex karyotype.

Authors:  Simone Feurstein; Frank G Rücker; Lars Bullinger; Winfried Hofmann; Georgi Manukjan; Gudrun Göhring; Ulrich Lehmann; Michael Heuser; Arnold Ganser; Konstanze Döhner; Brigitte Schlegelberger; Doris Steinemann
Journal:  BMC Genomics       Date:  2014-09-11       Impact factor: 3.969

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.